Bellerophon Therapeutics, Inc. (BLPH)

Bellerophon Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Net Income	-11.67	-19.83	-17.76	-24.73	-13.27	2.81
Depreciation & Amortization	0.01	0.07	0.1	0.15	0.35	0.36
Share-Based Compensation	0.58	0.79	1.13	1.63	2.15	2.96
Other Operating Activities	-1.26	1.21	-6.29	3.06	-2.17	-21.63
Operating Cash Flow	-12.34	-17.77	-22.82	-19.88	-12.94	-15.5
Change in Investments	-	-	-	-	-	-3
Other Investing Activities	-	-	-	-	-	6
Investing Cash Flow	0	0	0	0	0	3
Common Stock Issued	1.44	0	0	54.7	6.24	0
Share Repurchases	0	0	0	0	0	-0.03
Other Financing Activities	3.57	-0.04	-	2.87	-0.07	0.14
Financing Cash Flow	5.01	-0.04	0	57.57	6.17	0.17
Net Cash Flow	-7.23	-17.81	-22.82	37.68	-6.77	-12.33
Free Cash Flow	-12.34	-17.77	-22.82	-19.88	-12.94	-15.5
Free Cash Flow Margin	-218.78%	-	-	-	-	-
Free Cash Flow Per Share	-1.01	-1.86	-2.40	-2.55	-2.87	-3.57

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.